VABIOTECH has a strong focus on research and develop- ment of new products. The initial R&D activities that lead to the successful development of all the VABIOTECH’s commercialized human use vaccines including inactivated hepatitis A vaccine, plasma derived and recombinant hepa- titis B vaccine, inactivated Japanese encephalitis vaccine and oral cholera vaccine. The Company has achieved many significant development milestones that exemplify its core R&D competencies, inclusive of developing the first cell based, adjuvant A/H5N1 vaccine in Viet Nam in 2007.